作者:Sampath-Kumar Anandan、John S. Ward、Richard D. Brokx、Mark R. Bray、Dinesh V. Patel、Xiao-Xi Xiao
DOI:10.1016/j.bmcl.2005.02.075
日期:2005.4
Inhibitors of histone deacetylases (HDAC) are emerging as a promising class of anti-cancer agents. A mercaptoamide functionality was designed as a bidentate zinc chelator and incorporated into the hydroxamic acid based SAHA (1) scaffold in order to identify non-hydroxamate compounds as potential inhibitors of histone deacetylases. Two sets of mercaptoamides 2 and 3 with varying spacer length were synthesized
组蛋白脱乙酰基酶(HDAC)的抑制剂正在作为一种有前途的抗癌药出现。将巯基酰胺官能团设计为双齿锌螯合剂,并掺入基于异羟肟酸的SAHA(1)支架中,以鉴定非异羟肟酸酯化合物作为组蛋白脱乙酰基酶的潜在抑制剂。合成了两组具有不同间隔长度的巯基酰胺2和3,并评估了其对HDAC的抑制活性。巯基酰胺2e,3b和3d的微摩尔抑制作用较低。